1 
BACKGROUND INFORMATION ON THE PROCEDURE 
1.1  Submission of the dossier 
The applicant Elan Pharma International Ltd submitted on 09 May 2003 an application for Marketing 
Authorisation to the European Medicines Agency (EMEA) through the centralised procedure for 
Prialt, which was designated as an orphan medicinal product EU/3/01/48 on 9 July 2001. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur  Prof. B. Flamion 
Co-Rapporteur  Dr. P. Salmon 
Orphan Drugs: 
Prialt was designated as an orphan medicinal product in the following indication:  Treatment of 
chronic pain requiring intraspinal analgesia.  
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
1.2  Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The procedure started on 26 May 2003. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 08 August 
2003. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 11 
August 2003.  
During  the  meeting  on  23-25  September  2003,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 25 September 2003. 
The applicant submitted the responses to the CHMP consolidated List of Questions on 25 May 
2004. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 7 July 2004. 
During the CHMP meeting on 27-29 July 2004, the CHMP agreed on a list of outstanding issues 
to be addressed in writing by the applicant. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on 4 November 2004. 
During  the  meeting  on  15-18  November  2004,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation under exceptional circumstances to Prialt on 18 November 
2004. The applicant provided the letter of undertaking on the specific obligations and follow-up 
measures to be fulfilled post-authorisation on 16 November 2004.  
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 21 February 2005. 
1/1 
EMEA 2005 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
